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Abstract
Background: For the first time in the history of HIV, new bio-medical interventions have been shown to be effective in
preventing HIV transmission. For these new HIV prevention technologies (NPTs) to have an impact on the epidemic, they
must be widely used. This study uses a discrete choice experiment (DCE) to: understand the relative strength of women’s
preferences for product characteristics, understand the implications for substitution away from male condoms, and inform
realistic modelling of their potential impact and cost-effectiveness.
Methods: A DCE was conducted among 1017 women in urban South Africa. Women were presented with choices between
potential women’s NPTs (microbicides, diaphragm, female condom) and ‘what I did last time’ (use or not use a condom)
with different HIV and pregnancy prevention effectiveness’ and prices. Choice probabilities are estimated using the nested
logit model and used to predict uptake.
Results: In this high HIV prevalence setting, HIV prevention effectiveness is the main driver of uptake followed by pregnancy
prevention effectiveness. For example a microbicide with poor effectiveness would have niche appeal at just 11% predicted
uptake, while a highly effective microbicide (95% effective against HIV and pregnancy) would have far wider appeal (56%
predicted uptake). Though women who reported not using condoms were more likely to choose the NPTs, at current very
high rates of male condom use in South Africa (60%), about half of microbicide uptake is projected to be among those
currently not using condoms.
Conclusions: Women are very interested in NPTs, especially if highly effective in preventing HIV and pregnancy. Women in
greatest need were also most likely to switch to the new products. Where products are not yet available for distribution,
proxy data, such as that generated by DCEs, can bring realism to overly optimistic uptake scenarios found in many current
impact models.
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Introduction
For the first time in the 30 year history of HIV, new bio-medical
interventions have been shown to be effective in preventing HIV
transmission [1]. These include new technologies (microbicides,
also called topical pre-exposure prophylaxis) and novel applica-
tions of existing antiretroviral drugs for treatment (e.g. oral pre-
exposure prophylaxis), and ‘‘treatment as prevention’’ to prevent
new HIV infections [1–3]. Further down the product development
pipeline are a number of multi-purpose prevention technologies
which prevent multiple reproductive health indications such as
HIV and pregnancy and/or sexually transmitted infections (STIs)
[4,5]. Such products are under development in the form of vaginal
rings, physical barriers (e.g. cervical barriers like the SILCS
diaphragm) or injectable compounds [6]. As yet, no information
exists on the value women place on products providing protection
against a range of outcomes, their predicted level of uptake, the
impact of their introduction on the use of male condoms, or data
upon which to predict use of products with multi-purpose
characteristics.
In the light of these new HIV prevention technologies (NPTs),
there has been much speculation and debate about the potential
for ‘risk compensation’ following the introduction of a partially
effective NPT [7]. This could arise where people have a ‘target
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risk level’ [7]; so, as a consequence of decreased risk of HIV
resulting from the NPT, risky behaviour is increased, which could
then undermine the effect of NPTs, and theoretically could
increase an individual’s total HIV risk [7]. Lessons from the
introduction of voluntary medical male circumcision and vaccine
trial participation have not provided conclusive evidence on risk
compensation [3,8,9]. To fully understand behaviour change
effects, further studies will need to be undertaken during actual
roll out [7]. However, in the absence of this, choice experiments
eliciting hypothetical preferences for switching from existing HIV
prevention product (condoms) to NPTs could provide critical
insights.
To estimate the impact of the introduction of NPTs and inform
decision-making on their optimal roll out strategies, mathematical
models have been widely used [10–21]. These models tend to
estimate the epidemiological impact and cost-effectiveness of these
NPTs and identify the key determinants that drive these outcomes.
To date such modelling studies have all assumed user uptake
curves that are not dependent on product characteristics, despite
numerous other studies on NPTs showing the importance of
product effectiveness on user acceptability and predicted uptake
[22–28].
This study uses a discrete choice experiment (DCE) to: explore
the effect of product characteristics (HIV prevention effectiveness,
pregnancy prevention effectiveness, the ability to use it in secret
and price) on women’s preferences for three potential NPTs
(microbicides, a cervical barrier, and the female condom) in South
Africa; identify potential substitution effects; and predict the
uptake of microbicides.
Methods: The Choice Experiment
This DCE aims to identify the key attributes of NPTs,
specifically microbicides, the diaphragm, and the female condom,
that drive women’s willingness and ability to use them within the
context of their own intimate lives. The formative research for this
study took place between June and August 2005 and the survey
took place in September 2005.
Ethics Statement
This study was approved by the ethics committees of the
University of the Witwatersrand in South Africa and the London
School of Hygiene and Tropical Medicine, UK. Written informed
consent was obtained from all participants.
The study context
This study was conducted at the same time and in a comparable
population, but in a different community, from a randomised
controlled trial of microbicides, the Microbicide Development
Programme 301 (MDP 301), conducted in South Africa, Zambia,
Uganda, and Tanzania between 2005 and 2009 [29]. Microbi-
cides are a class of products such as gels or tablets that a woman
can insert into her vagina to reduce the risk of acquiring HIV.
Although the MDP 301 trial products had no impact on HIV
acquisition [30], a subsequent trial (the CAPRISA 004 trial) of a
different microbicide product, found that tenofovir gel reduced
HIV incidence by 39%, increasing to 54% among high adherers
[3]. This was a breakthrough, with the HIV community eagerly
awaiting the results of a further trial to confirm these results in
2014 [31].
Concurrent with the MDP 301 trial, the MIRA trial, which ran
from 2003 to 2006, tested the effectiveness of the diaphragm in
preventing HIV acquisition among women in South Africa and
Zimbabwe; this trial also did not show an effect [32]. Recently the
SILCS diaphragm has been developed and is expected to provide
protection against pregnancy and cervical STIs similar to the
traditional diaphragm [33]. It could also be used as a microbicide
delivery system thus providing multi-purpose prevention. Though
a new device, insights from studies of the traditional diaphragm
are still likely to be informative for uptake.
At the time of this study, the price of the female condom, at 18
times that of male condoms, was considered prohibitively
expensive for wide scale distribution. Female condoms were
available in South Africa in a limited number of clinics [34] and
were rationed by health care workers, moreover there was limited
knowledge of female condoms among women in the general
population. Innovations to the female condom characteristics are
reducing price and there is renewed support for its distribution in
South Africa [35]. It is therefore the right time to prepare for the
introduction of NPTs and consider factors affecting their potential
demand.
Development of the discrete choice experiment
The DCE was developed based on an intensive qualitative
phase including individual and group interviews during the three
months prior to the household DCE survey. This formative phase
aimed to inform the design of the DCE scenarios, and identify key
product characteristics (attributes) and their variations (levels) by
understanding challenges women face in accessing and using
existing HIV prevention technologies and the most appropriate
representation of the attributes. An example of an attribute could
be price, with levels being the specific prices, say 0, 5, 10, 20. Ten
focus group discussions (FGDs) were held among older (30–50
years old) and younger (18–29 years old) women, i.e. five among
each. Women were recruited from clinic attendees and from
within the community. The FGDs took place in the local clinic’s
training room on Saturdays. Weekly FGD topic guides were
finalised based on the findings from the preceding week.
Subsequently, two attribute reduction workshops were held, where
individual questionnaires were completed by women in a group
interview setting with the aim of identifying the most important
attributes of products from the long lists generated in the FGDs.
Women were asked to rank lists of characteristics based on their
most and least preferred options and the interpretation of
alternative questionnaire wording and pictorial representations
of attribute descriptions were explored to ensure the survey tool
was capturing what it was intended to capture [36]. Finally, 10
individual interviews/pilot interviews were undertaken to under-
stand women’s interpretation of the scenarios presented, such as
the presentation of HIV and pregnancy prevention effectiveness.
Results from the qualitative phase can be found in MacPhail et al.
2009 [37]. In the final design of the qualitative research, policy
objectives and likely realistic levels of product attributes were
considered; the final five attributes were product (microbicide,
diaphragm and female condom), pregnancy prevention effective-
ness, HIV prevention effectiveness, the ability to use it without the
partner’s knowledge and price. The attributes and their levels can
been seen in Table 1.
HIV and pregnancy effectiveness: The levels of expected
HIV effectiveness of the product were developed based on the
then-ongoing trials of single dose pre-coital microbicides
(MDP301 in Uganda, Tanzania, Zambia, South Africa [30])
and the diaphragm (MIRA in South Africa and Zimbabwe [32])
and existing evidence on condom effectiveness, starting from as
low as 35% reduction in HIV risk for microbicides and the
diaphragm and 75% for the female condom (representing typical
use and accounts for breakage and slippage) to 95% reduction in
HIV risk, comparable with expected effectiveness of the male
Uptake of HIV Prevention Products in South Africa
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condom under perfect use. Pregnancy prevention effectiveness
levels for microbicides and the diaphragm were based on
discussions with the scientific teams of the MDP 301 and MIRA
trials, respectively.
Ability to use in secret: Ability to use women’s HIV
prevention technologies discreetly was reported as more important
than pure covert use [38]. Pure covert use is considered where the
partner cannot know of product use, whereas discreet use is
defined as being able to use the product without the partner’s
active participation. Just over half of women in a user trial chose to
use the microbicides and diaphragm without informing their
partners [39]. The female condom, though not secret, does not
require the male partner’s active participation. The ability to use
the product in secret was included in two levels (possible or not
possible to use without partner knowing) for microbicides and the
diaphragm, while male and female condom use would always be
known to the partner.
Prices: Prices were developed based on suggestions from FGD
participants for the various products and prices of condoms
distributed through the public, social marketing and private sector
distribution channels in South Africa (Free, US$0.54, US$1.04,
and US$2.08 (South African Rand (R)0, R5, R10, R20 ))[40]. To
reflect the reusability of the diaphragm and the reported higher
valuation by women in the FGDs, diaphragm prices were set at
four times the price levels of the other NPTs (Free, US$4.16, US$
8.32, US$16.64 (R0, R20, R40, R80)) [40].
Opt out: An opt-out option was included as represented by ‘I
would do what I did last time I had sex’, which was then
represented by what women had reported earlier in the
questionnaire (having used or not having used a condom during
their last sex-act). The attribute levels of the opt-out were then
presented consistent with the attributes of the reported protection
in last sex-act (Table 1, alternative C).
The final design of the choice sets was a compromise between a
behavioural model of choice, emphasising realism of choice sets
and alternatives, and statistical models, emphasising the need for a
parsimonious design. This was obtained using the ORTHOPLAN
procedure in SPSS.
The choice task
The unlabelled DCE consisted of six choice tasks with three
alternatives in the format presented in Figure 1. This DCE asked
women to think back to their last sex-act, and choose if they would
have switched to one of the new options (A or B) or if they would
have done the same that they actually did in their last sex-act
(alternative C) (Figure S1 in File S1).
A two-sided opt-out card presented attribute levels for
condoms, or non use of condom. The card was placed in the
utmost right column as the opt-out choice. The interviewer could
thus place the card over the third option, with the side up to
correspond to the scenario of their last -act (having used a
condom or not), and specify the appropriate attribute levels. The
availability of female condoms was very low, so by framing the
opt-out as male condom or use no HIV protection and the new
products as the main alternatives, the full range of technologies
for HIV prevention that were available or in trials in 2005 were
represented.
Sampling and data collection procedures
Women were eligible to participate if they were between 18 and
45 years of age and had been sexually active in the past six
months. Sample randomisation occurred at three levels: geo-
graphical area, household, and within households, if there was
more than one eligible woman in a selected household. A
representative sample of 1017 eligible women from three adjacent
communities in Ekurhuleni Metropolitan Municipality south-east
Johannesburg were interviewed in their homes. Of 2026
households approached, 29% did not have any eligible women,
10% were not at home after three visits. Refusal rate was just 3%,
though an additional 3% postponed and could also be considered
Table 1. DCE physical attributes and levels.
Alternative A,B C
Neither, I would do what I did the last time I had
sex*
Attribute Levels
Product Microbicide (MCD), Diaphragm (DGM), Female
Condom (FC)
Male Condom(MC) No protection (None)
Effectiveness in preventing HIV
(MCD, DGM) 35%, 55%, 75%, 95% 95% 0%
(FC) 75%, 95%
Effectiveness in preventing pregnancy
(MCD) 0%, 55%, 75%, 95% 95% 0%
(DGM,FC) 75%, 95%
Ability to use without partner’s knowledge
(MCD, DGM) Cannot be used in secret, Can be used in secret Cannot be used in secret Can be used in secret
(FC) Cannot be used in secret
Price in US dollars
Single use product (MCD, FC) Free, US$0.54, US$1.04, US$2.08 Free Free
Reuseable product (DGM) Free, US$4.16, US$ 8.32, US$16.64 Free Free
MCD: microbicide; DGM: Diaphragm; FC: Female condom; *Depending on what they did the last time they had sex, a card was placed over the attributes with the
appropriate attribute levels for either using a male condom with its attributes, or no protection.
doi:10.1371/journal.pone.0083193.t001
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refusals. A further 4% had missing reasons, other reasons or were
incorrectly sampled. The sample realisation (number of completed
interviews per household approached) was 51%.
This paper-based survey was administered by 17 locally
recruited and trained female fieldworkers. The community survey
questionnaire consisted of four sections. The first collected
background data on the respondent, including indicators of
socio-economic status (education level, type of housing, and an
asset index). The second section collected reproductive histories,
including experience with existing HIV prevention technologies:
what they use, where they obtained it, if they had or had not used
a condom in their last sex-act. This describes the ‘neither’ option.
The reproductive histories also included information about
contraceptives, life stage questions (current type(s) of sexual
partnership(s) and desire for pregnancy), and the respondent’s
perceived HIV risk. The method that was used last time reveals
preferences for (and ability to use) condoms - the existing method.
The third section presented an introduction to the range of HIV
prevention technologies and elicited preferences for products and
their attributes. A male condom, female condom, a diaphragm,
and a microbicide applicator filled with lubricant were available
for respondents to inspect, touch and ask questions about. This
was provided to reduce the hypothetical nature of the products.
An additional DCE was also administered to collect women’s
preferences for distribution outlet characteristics and promotional
messaging, results from this are reported elsewhere [41]. The last
section consisted of questions evaluating the interview and eliciting
participant feedback on the questionnaire.
Self-reported behaviour data can be subject to social desirability
bias and choice experiments subject to hypothetical bias,
potentially leading to upwardly biased results. Hypothetical bias
refers to the inconsistency between reported behaviour and
observed behaviours, when the reported choice does not require
real action [9]. In the case of NPTs another layer of hypothetical
bias is introduced by the fact that the products do not exist on the
market and have not been experienced by the participants. This
study aimed to reduce hypothetical bias in two ways. Firstly, by
framing the scenarios within the context of the respondent’s last
sex-act (what Henscher calls ‘‘referencing around a real world
experience’’ [9]), the researchers aimed to provide a less
hypothetical use scenario. Secondly, respondents were also shown
actual product prototypes and were able to handle them, but could
of course not experience them in a real setting within the context
of this study. Social desirability bias relates to respondents’ desire
to report socially acceptable behaviour and underreport higher
risk behaviours, and has been widely observed in the field of HIV
research on self reported sexual behaviours [8]. Efforts were made
to emphasise to respondents that there were no right or wrong
answers. However, in urban South Africa people are inundated on
a daily basis with safer sex messaging. It is likely that this has both
biased upwards reports of condom use in the last sexact, and
women’s choices in favour of alternatives with very high HIV
effectiveness. However, we must also not underestimate the
Figure 1. An example of the choice task.
doi:10.1371/journal.pone.0083193.g001
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prominence of HIV in South African women’s daily lives and the
value women place on having usable HIV prevention options. Due
to these potential biases, this study’s uptake predictions may
represent the upper limits of what may be expected in reality. This
can then generate an upper bound uptake prediction for use by
impact modellers.
The questionnaire was translated into the two most common
non-English languages in the recruitment areas (Sesotho and
isiZulu); then translated back for validation.
Methods: Statistical Analysis
Sample generalisability
A review of the household and individual characteristics of the
study participants was undertaken using basic descriptive statistics.
Generalisability was assessed by comparing women’s socio-
demographic characteristics with those from two nationally
representative surveys in South Africa: the South Africa Demo-
graphic and Health Survey from 2003 [42] and the South African
National HIV Prevalence, HIV Incidence, Behavioural and
Communication Survey, 2005 (known as the Nelson Mandela
Survey) [43].
Participant feedback
In addition to open ended questions on participants’ experience
of the survey, we asked three closed ended questions: What did
you think of the scenarios we presented? Easy, difficult, confusing;
Were they interesting or boring? Were there too many or too few?
We present summary statistics on these to provide an overview of
participant feedback.
Model specification
The basic workhorse for estimating discrete choice models
remains the multinomial logit (MNL) model. However, it is based
on a rather stringent restriction on substitution behaviour between
alternatives, known as ‘‘independence of irrelevant alternatives’’
(IIA) (for more detail see Green 2000 p. 864 or Henscher et al p.
518) [44,45]. The nested logit (NL) model is a popular alternative
to the MNL model as it relaxes the IIA assumption while
maintaining ease of computation. It depicts choices in hierarchical
levels with partitioned choice sets. Within a partition (branch), IIA
must hold, but between the branches the model relaxes the IIA
assumption. The NL can explicitly model ‘non-participation’ (the
no-change choice) [46], which is particularly attractive to this
application. Further details of this model and the NL tree structure
can be found in File S1.
The outputs of discrete choice models are relative utilities. The
simplest form of the model incorporates only design attributes in
the utility function, i.e. main effects: product (microbicide (MCD),
diaphragm (DGM), female condom (FEMC)); ability to use in
secret (SECR); effectiveness against HIV (HIV); effectiveness
against pregnancy (PREG); and Price (specified as ln(price+1))
(PRICE) and interactions between product and effectiveness
(DGMPREG, MCDPREG, DGMHIV, MCDHIV). The price
specification followed extensive exploration, using partworths to
allow fully free utilities for each price and identifying the
functional form of price that fit best. We settled on the logarithm
of price+1. The 1 was added as log of price 0 cannot be obtained.
Non-linear relationships for pregnancy and HIV effectiveness
were explored but not identified. Interactions between attributes
were explored, in particular whether women value pregnancy
and HIV prevention effectiveness differently between the
products.
The utility function of main effects for switching, depending on
if the not switch option was a condom or nothing, is represented
by:
Vnotswitch{main~bNoChange NoChangezbMCLast MCLast
.
The main effects utility function for the NPTs is represented by:
Vnew{main~bdgm DGMzbmcd MCDz
({1  (bdgmzbmcd )  FEMC)zbsecr  SECRz
bpreg  PREGzbHIV HIVzbln (price)  PRICEz
bdgmprg DGMPRGzbmcdprg MCDPRGz
bdgmhiv DGMHIVzbmcdhiv MCDHIV
.
Beyond main effects we expect a number of variables related to
women’s situations and experiences to be important in their
willingness and ability to use NPTs. In unlabelled (generic) designs,
variations among women in preferences for the products and their
attributes are explored by including interactions with women’s
socio-demographic characteristics. Note that in labelled designs,
interactions can be entered directly into the utility function. It is
hypothesised that the choice to switch to any of the NPTs could be
affected by the utility of their current practice (use of a male
condom in last sex-act (MCLastS)), having ever experienced
difficulties getting a partner to use a male condom (DiffMC), or
cohabiting (Cohab). This creates the following utility function for
the choice to switch or not:
Vnot switch{SDC~Vnot switch{mainzbDiffMC DiffMCz
bCohab  Cohab
.
It is hypothesised that the preference for:
N products is different for women who used a condom relative to
those who did not (DGM*MCLastS, MDC*MCLastS, FEMC*
MCLastS );
N being able to use a product in secret is different for women
who had experienced difficulties getting their partner to use a
male condom in the past (SECR*DiffMC);
N pregnancy prevention effectiveness is different for women who
are living with their partners (PRG*Cohabiting) than those who
are not, because of their life stage/circumstances relating to
the consequence (positive or negative) of conception;
N HIV prevention effectiveness is different for women who
consider themselves at higher risk of becoming HIV infected
(HIV*self perceived risk of HIV );
N HIV prevention effectiveness is different for women who are
cohabiting (HIV*Cohab).
This generates the following utility function for the choice
between NPT alternatives:
Uptake of HIV Prevention Products in South Africa
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Vnew{SDC~Vnew{mainzbdgm MCLastS DGM MCLastSz
bmcd MCLastS MCD MCLastSz
({1  (bdgm MCLastSzbmcd MCLastS)
FEMC)zbSecrDiff  SECR DiffMCz
bpreg Cohab  PRG Cohabz
bHIVrisk  RiskHIVzbHIV Cohab HIV Cohab
Effects coding has been used for categorical variables. This
means that the coefficients must be interpreted as divergence from
the imposed mean of 0 for that attribute. To retrieve the
coefficient of the omitted category, we take [–1*gcoefficients other
levels in attributes]. Not including a constant in the estimation
imposes a mean utility of 0 [47], with coefficient values
representing relative strength of preferences. A constant is used
for labelled experiments to capture the mean value of the label,
however for generic experiments this is meaningless since A and B
have no useful meaning, and would capture a preference for the
left hand side option over the right hand side option.
NLOGIT 3.0 was used for estimation. Using its simulation
command, predicted market uptake for microbicides with varying
characteristics is estimated for condom and non-condom users,
and a weighted average is used to predict population uptake, based
on the women’s reported condom use at last sex-act (60.4%) in
2008 [48].
Results
Data description
The sample included 1017 adult women (18 to 45 years old),
with an average age of 31.5 years (Table 2). The largest category of
participants had entered but not completed secondary school
(45%); only 27% finished secondary school. More than a third
were employed and just under a third lived in a household that
had a working car. This is close to the national averages among
adult urban women in South Africa.
The sexual and reproductive lives of women in this sample were
also comparable to other representative surveys [42] [43], with 1.8
children per woman, and 72% having ever used modern
contraception and 31% reporting having used a condom in their
last sex-act. Though 39% had ever seen a female condom, less
than 3% had ever used one. Current use of contraception appears
lower than the average urban sample, at 40% versus 51% [42].
Just over half of the sample was cohabiting with their partner and
38% had ever experienced difficulties getting their partner to use a
condom. There was a fairly even distribution across the various
categories of self perceived HIV risk.
Participants were asked about their preferred HIV prevention
product, after receiving a detailed description. Microbicides were
chosen as preferred product by 48% of respondents, followed by
the diaphragm chosen by 28% of respondents. The female and
male condoms were least preferred, chosen by 13% and 10%,
respectively. Though these results give relative preferences for the
full product, DCE can separate out drivers of these choices based
on specific product characteristics.
Table 2. Sample descriptive statistics.
This sample*
Demographic & Health Survey
2003 [42]
Urban sample
Socio economic status indicators
Age (age) 31.5 years
Education: started but did not complete secondary school 45% 47%
Employed part or full time (emplyd) 35% 42%
Ownership of a car 31% 33%
Reproductive health profiles
Number of children 1.8 1.6
Ever use of contraceptives 72% 73%
Current use of modern contraception 40% 51%
Condom used at last sex-act (MCLastS) 31% 29%
Female condom – ever seen 39%
Female condom – ever used 3%
Cohabiting with sexual partner (Cohab) 55%
Ever experienced difficulties getting partner to use condoms (DiffMC) 38%
Self-perceived risk of HIV **– high (RiskH) 22%
Self-perceived risk of HIV – medium (RiskM) 26%
Self-perceived risk of HIV – low (RiskL) 23%
Self-perceived risk of HIV – no (RiskNo) 26%
*The denominator of the proportions for ‘This Sample’ are based on the full sample, ranging from 1012 to 1017 to account for some missing responses.** The risk
question was posed as: ‘‘Do you consider yourself at high medium, low, or no risk of getting HIV or becoming re-infected?’’ No further quantification was provided and
therefore was the individuals subjective valuation of these categories. Risk is an ordinal variable that is used as a cardinal measure in the model estimates, valued as 0
for ‘No risk’ to 3 for ‘High risk’.
doi:10.1371/journal.pone.0083193.t002
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Table 3 provides an overview of the choices made according to
women’s characteristics that are hypothesised to have an effect on
their choice behaviour. ‘Change’ represents choosing one of the
alternatives of NPTs, while ‘not change’ represents the alternative
‘do what I did last time I had sex’. Of the 6101 choices (6 choice
sets*1017 women and 1 missing response) possible across the full
sample of respondents, if left to chance, choices would fall equally
across the three alternatives: two-thirds of the responses would be
expected for ‘change’ and one-third would be expected for ‘not
change’. Seventy-four percent of choices were in favour of a NPT,
26% were for ‘not change’. Women who used a male condom
appear less likely to change to one of the NPTs: in 56% of their
choices they chose one of the NPTs versus 83% of women who did
not use protection. This suggests that preferences for the NPTs are
likely to differ between women who were and were not able to use
a male condom in their last sex-act. Other groups of women with
high switching responses were: those currently using contracep-
tives (80%), those who experienced difficulties using condoms
(82%), and those who perceive themselves at high risk of HIV
(83%).
Potential reporting bias and participant feedback
Though the interview was intended to be undertaken in private,
participants sometimes encouraged the interview to go ahead
despite the presence of others (16% of interviews, mostly in the
presence of children). As the vast majority were done in private, we
do not expect a large impact on the results.
To allow for review of reporting bias, in 20% of the sample a
DCE-like scenario was included with the three potential current
alternatives: male condom, female condom or use no barrier
method, with their respective attribute levels. Of women who
reported using a male condom in their last sex-act, 59% reported
they would have used a male condom and 33% chose the female
condom; however of those who did not use a condom only 13%
chose the no condom option. This suggests that women’s choices
were based more on their intentions for a future sex-act than on
what would have happened in their last sex-act.
At the end of the DCE survey, participants were asked about
their experience of making the DCE choices. About three-quarters
found them easy (74%), 23% found them confusing, and 3% found
them difficult. The choices were considered interesting by 95%,
boring by less than one percent and neither by almost five percent.
However 42% stated there were too many scenario choices.
Estimation results
Preferences: Table 4 shows the results of the MNL and NL
models without (models I and II, respectively) and with socio-
demographic characteristics interactions (models III and IV,
respectively). The likelihood ration (LR) test was used to identify
the best fitting model, i.e. reject a restricted model. The basic
MNL model (model i) is rejected in favour of the more flexible NL
model (model 2). Subsequently model 2 is rejected in favour of
model IV, which allowed for preferences to vary by women’s
characteristics. From here onwards we focus on model IV.
The utilities from Table 4 are presented graphically in Figure 2.
The top section of Figure 2 shows the relative strength of
preferences for products and their attributes based on model IV,
while the bottom section shows the highest and lowest valuations
for each of the three products based on their possible attributes
(secrecy and prevention effectiveness’). It is worth noting that by
using effects coding the average utility for all attributes is set to 0.
Of the different products, the preferences for the diaphragm
and microbicides were very positive and of similar magnitude,
while the female condom was significantly less preferred. This
pattern varied from the directly elicited preferences for products,
where microbicides were chosen as preferred product by 48% of
Table 3. Switching responses by women’s characteristics.
Change Not-change
Count % Count %
All 4,539 74% 1562 26%
Condom used at last sex-act (MCLastS) No 3,466 83% 727 17%
Yes 1,073 56% 835 44%
Cohabiting with sexual partner (Cohab) No 1,926 70% 810 30%
Yes 2,613 78% 746 22%
Ever experienced difficulties getting partner to use condoms (DiffMC) No 2,624 69% 1156 31%
Yes 1,890 82% 401 18%
Employed (emplyd) No 2,902 73% 1058 27%
Yes 1,637 76% 504 24%
Self-perceived risk of HIV (RiskH) High 1,105 83% 232 17%
(RiskM) Medium 1,198 77% 362 23%
(RiskL) Low 1,043 74% 361 26%
(RiskNo) None 1,019 65% 547 35%
Means Means
Household SES (SEShh) –0.006 0.018
Age (age) 31.86 30.58
Years of education (EducYrs)* 10.00 10.14
*The original variable was ordinal in terms of level of education attended and completed. This was transformed into an average number of years in education to obtain
a continuous variable.
doi:10.1371/journal.pone.0083193.t003
Uptake of HIV Prevention Products in South Africa
PLOS ONE | www.plosone.org 7 December 2013 | Volume 8 | Issue 12 | e83193
respondents, followed by the diaphragm chosen by 28% of
respondents. The female and male condoms were least preferred,
chosen by 13% and 10%, respectively. DCE can separate out
drivers of these choices based on product characteristics.
Secrecy has a significantly positive, but small, effect on choice
probability, while price was significantly negative, consistent with
economic theory. The most important characteristics were the
level of protection against pregnancy and HIV. The negative
interaction terms between diaphragm and HIV and between
pregnancy and microbicides, respectively, shows that women find
the HIV effectiveness of the diaphragm less important and the
pregnancy effectiveness of microbicides less important. Synergies
between preferences for pregnancy- and HIV- effectiveness were
explored by including their interaction terms in an earlier model,
but these terms were small in magnitude and did not approach
statistical significance and therefore not included in the final model
specification (results available upon request).
Table 4. Estimation of determinants of preferences for new HIV prevention technologies and their attributes with interactions.
Model I Model II Model III Model IV
Multinomial Logit Nested Logit Multinomial Logit Nested Logit
Coeff. Std. err Coeff. Std. err Coeff. Std. err Coeff. Std. err
Main effects
Diaphragm (DGM) 0.590 ** 0.235 0.619 ** 0.293 0.597 ** 0.242 0.636 ** 0.289
Microbicide (MCD) 0.364 * 0.218 0.741 *** 0.280 0.284 0.225 0.604 ** 0.276
Female condom (FEMC){ –0.953 *** 0.368 –1.360 *** 0.472 –0.882 ** 0.379 –1.240 *** 0.464
Ability to use in secret (SECR) 0.040 0.026 0.047 0.032 0.062 ** 0.027 0.068 ** 0.032
Pregnancy effectiveness (PRG) 1.431 *** 0.159 1.757 *** 0.195 1.457 *** 0.163 1.741 *** 0.195
HIV effectiveness (HIV) 3.285 *** 0.159 4.439 *** 0.214 2.974 *** 0.171 3.697 *** 0.230
LN(Price) (LNP) –0.093 *** 0.015 –0.133 *** 0.019 –0.088 *** 0.016 –0.121 *** 0.019
Attribute interactions
DGM*PRG –0.195 0.223 –0.081 0.281 –0.163 0.229 –0.076 0.277
MCD*PRG –0.346 ** 0.169 –0.502 ** 0.208 –0.315 * 0.173 –0.449 ** 0.206
FEMC*PRG{ 0.541 * 0.286 0.583 0.361 0.478 0.293 0.526 0.355
DGM*HIV –0.543 *** 0.186 –0.616 *** 0.223 –0.521 *** 0.191 –0.569 *** 0.221
MCD*HIV 0.261 0.183 –0.012 0.230 0.312 * 0.188 0.077 0.227
FEMC*HIV{ 0.282 0.280 0.628 * 0.354 0.209 0.288 0.492 0.348
Interactions with women’s characteristics
DGM*Used condom last sex-act (MCLastS) 0.133 *** 0.035 0.145 *** 0.042
MCD*MCLastS –0.053 * 0.031 –0.048 0.038
FEMC*MCLastS{ –0.080 ** 0.035 –0.097 ** 0.042
SECR*ever difficulties negotiating condoms (DiffMC) 0.092 *** 0.023 0.101 *** 0.027
PRG* cohabiting –0.087 0.080 –0.141 0.094
HIV* self perceived risk of HIV 0.290 *** 0.037 0.494 *** 0.074
HIV*Cohab –0.176 0.109 –0.351 ** 0.137
LNP*employed (EMP) 0.038 *** 0.011 0.044 *** 0.016
Choose ‘do the same as last time’ (C) (NOSWITCH) 2.948 *** 0.203 0.548 ** 0.225 3.063 *** 0.211 1.092 *** 0.219
C*MCLastS 0.632 *** 0.036 0.614 *** 0.035
C*DiffMC –0.267 *** 0.036 –0.250 *** 0.035
C*Cohab –0.177 * 0.102 –0.142 ** 0.062
Inclusive values –Change 0.315 *** 0.043 0.416 *** 0.042
Not Change 1.000 .....(Fixed 1.000 .....(Fixed
N 6,101 6,065
Ll-function –5,907.479 –5,821.433 –5,547.393 –5,484.865
Model 1 versus 2 Model 2 versus 4
LR df 1 11
LR test stat 172.093 673.14
LR p-value 0.00 0.00
*is significant at a P-value,0.1. ** is significant at a P-value,0.05. *** is significant at a P-value,0.01.
{retrieved coefficient by swapping the omitted category.
doi:10.1371/journal.pone.0083193.t004
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The relative utilities of the best and worst product packages
were estimated, see figure notes for how these were defined.
Although the diaphragm and microbicides have similar best
product valuations, the worst diaphragm and female condom are
preferred to the worst microbicide due to the restrictions on their
lowest pregnancy effectiveness levels (75%) thus placing a floor on
their relative utilities. Microbicide preferences were elicited
including product profiles that provided no protection against
pregnancy.
Table 4 presents the full model results which allow for
exploration if one characteristic can compensate for another.
The main effects show clear trade-offs that women would be
willing to make. For example, a non-contraceptive microbicide
would need to have 82% HIV effectiveness to be equal to a 55%
effective diaphragm with 75% pregnancy protection.
A number of interactions are included to explore the effect of
women’s characteristics on their product valuations (Table 4).
How women’s values for these products are affected by their
current HIV prevention options/choices was explored by inter-
acting the NPT with women’s reported condom use in their last
sex-act. Having used a condom in the last sex-act implies using a
condom is a feasible option, however having not used one may
mean that it is not an option or that it is an option but the choice
was not to use one. Women who used a condom last time have
higher marginal valuations for the diaphragm and lower
valuations for the female condom than women who did not use
a condom. Secrecy was significantly more important to women
who had ever experienced difficulties getting a partner to use a
condom.
Women who were living with their partners had less strong
preferences (lower marginal utilities) for HIV prevention effec-
tiveness, potentially reflecting that cohabiting women were not as
worried about HIV. Their preferences for pregnancy prevention,
however, were not significantly lower than non-cohabiting women.
Women who considered themselves at higher risk of acquiring
HIV valued HIV prevention effectiveness more strongly. And
lastly employed women had less negative coefficients for price,
which implies higher willingness to pay, consistent with economic
theory.
The choice to switch from what a woman did last time she had
sex represents either newly protected sex-acts, if the woman had
not used a condom in her last sex-act, or it represents substitution
away from the condom, if she had used a condom. The value of
not switching is allowed to differ if the last sex-act was or was not
protected by a condom. If the woman used a condom, her relative
utility is C+C_MCLastS, and if she did not it is C-C_MCLastS.
Generally, the high value of the coefficient shown for not switching
suggests the expected reporting bias towards switching may not be
as strong as hypothesised. Women who used a condom value not
switching three and a half time times more than those who did not
use a condom. Having had difficulties in negotiating condoms
(DiffMC), living with a partner (Cohab), and currently using
contraceptives (Contr) decrease the relative utility of not-changing
and thus also its probability. A woman with these characteristics
and who did not use a condom in their last sex-act is predicted to
have a near 0 utility for the Not Switch alternative (1.092-.614--
0.25--0.142= 0.08). In contrast, a not-cohabiting woman who has
never had a problem using condoms, used a condom in her last
sex-act and is not using contraception has a relative utility of 2.10
for not switching, thus is far less likely to take up one of the NPTs.
Substitution and predicted uptake: Figure 3 presents
predicted uptake of a microbicide with varying characteristics.
From the choice probabilities, it can be seen that for all levels of
the product attributes, women who had not used a male condom
considered microbicides a more attractive choice than women who
had used condoms. The HIV prevention effectiveness of a product
played an important role in women’s choices, with a low projected
uptake of a microbicide with poor effectiveness (11%), increasing
Figure 2. Relative preferences for products and their characteristics. Note: All full product preferences are based on free distribution. Best
profiles are specified as microbicides and the diaphragm able to be used in secret and with 95% protection against pregnancy and HIV for all
products. Worst profiles are specified as not being able to be used in secret and the lowest product specific effectiveness included in the experiment
(i.e. prevention effectiveness: 75% for the diaphragm and female condom and 0% for microbicides; for HIV prevention effectiveness: 35% for the
diaphragm and microbicide and 75% for the female condom).
doi:10.1371/journal.pone.0083193.g002
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to 34% for a product with high effectiveness against HIV and no
effectiveness in preventing pregnancy. Pregnancy prevention was
also important to women and would enhance the attractiveness of
a microbicide, facilitating its use to a very high level: up to 65%
among those not using a condom. This shows that the effectiveness
of microbicides in both HIV and pregnancy prevention will be a
major determinant of their uptake by women, driving uptake levels
from 9% to 51% if a woman had used a condom or from 14% to
65% for those who had not used a condom in their last sex-act.
Discussion
This paper has focussed on identifying how women value
different physical product characteristics for technologies to
prevent HIV infection and predicting uptake levels. It is the first
study to go beyond qualitative acceptability studies to quantify
women’s preferences for NPTs and their trade-offs between
product characteristics. The nested logit model applied uses a two-
step approach in which the choice to use a NPT (substitution from
what they did last time) is modelled separately from the choice
among the NPTs, which allows us to explore potential substitution
away from male condoms, a concern raised by policy makers and
potential users alike [7,49].
When choosing among the NPTs, microbicides and the
diaphragm are generally preferred to the female condom.
Although ability to use the product in secret may have a very
small impact on women’s choices in general, this characteristic is
important to women who had experienced difficulties getting men
to use a condom. Women who had used a condom appeared more
satisfied with their status quo and were less likely to try alternative
methods, while women who had ever experienced difficulties
getting their partner to use a condom and/or were living with their
partners were more likely to try the NPTs.
HIV prevention effectiveness is the characteristic most impor-
tant to women and appears to dominate most choices. Women
were able to understand the relative importance of the range of
effectiveness levels presented, indicated by low predicted uptake of
products with low effectiveness, consistent with Gafos et al. [49].
Although HIV effectiveness is more than twice as important as
pregnancy prevention, it is especially important to women who
consider themselves at higher risk of becoming HIV infected. This
is consistent with a number of other stated preference studies on
preference for new HIV prevention interventions [23–28].
Researchers in the field of NPT acceptability have raised the
issue of the large divergence between reported acceptability and
subsequent use [50]. In this study, though 90% of women
expressed interest in trying a microbicide, overall uptake in urban
South Africa is projected to be far more modest, suggesting around
one in eight women would be willing to use a 55% effective gel
(about the effectiveness of tenofovir 1% gel in the CAPRISA 004
trial [3] ) with no pregnancy protection; this is likely to reach a
niche market segment. A highly effective microbicide (95%
Figure 3. Predicted uptake of microbicides among women who had and had not used a condom. Figure 3 shows the probability of
switching to a microbicide with different levels of HIV prevention effectiveness, pregnancy prevention effectiveness and price, according to whether
she had used a condom or not in her last sex-act and predicted population level uptake. The choice is between the microbicide and a free female
condom (with 95% protection against HIV and pregnancy), or neither. The light bars on the left are the probabilities for women who reported having
used a condom in their last sex-act, on the darker bars on the right are the probabilities for women who had not used a condom in their last sex-act,
the vertical line shows the predicted population level. The base case is modelled close to the CAPRISA 004 trial effectiveness results (54% effective
against HIV and no pregnancy effectiveness). On the very left, it can be seen that an expensive microbicide with low prevention effectiveness would
have a low probability of being chosen. As the product characteristics improve (towards the right of the figure), women find the product becomes
more and more attractive relative to the female condom or what they did last time.
doi:10.1371/journal.pone.0083193.g003
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protection against HIV) is likely to be far more attractive,
potentially providing protection for about 40% of women who
were not using condoms. A product with both high HIV
protection and high pregnancy protection (95% each) may have
wide interest, potentially providing prevention for around half of
urban South African women, with highest uptake among those not
using condoms (up to 65%). As mentioned earlier, these estimates
should be considered upper bounds, given the potential for
upward biased reporting of women’s likelihood of using new
products.
Figure 4 shows the assumptions recent (2010–2013) modelling
studies have made around uptake of oral pre-exposure prophy-
laxis, microbicides and vaccines coverage [10–13,15,17–19]. Early
studies aiming to model the potential epidemiological impact
assumed particularly high values for uptake and/or use. Though
we see more realistic coverage levels being modelled over time,
none of the existing studies take into account the interaction
between product effectiveness and uptake.
This study suffers from a number of limitations. Reporting
biases are inherent in survey based data, and may be of greater
concern when collecting intimate sexual data. Though all efforts
were made to undertake the interviews in private, 16% of
interviews were undertaken in the present of others. The impact of
the presence of others on choice responses will be explored in
future analysis of these data. This study use an experimental design
which was the state of the art in 2005, however many advances
have been made with DCE experimental design approaches since
then. If repeated today, we would use the NGENE package to
generate an efficient design using pilot data to generate parameter
priors. This would have generated a far smaller design and have
allowed for a smaller sample size [51].
Great advances been made in HIV prevention and treatment in
South Africa since these data were collected in 2005. We have seen
a dramatic increase in reported condom use and the expansion of
ART for treatment far beyond expectations, which may change
valuations. The changes in context could mean HIV prevention
technologies are more acceptable, potentially leading to higher
uptake, or could reduce the relative value of microbicides. Pre-
exposure prophylaxis and treatment as prevention have been
shown to be highly effective in preventing HIV among those who
have high adherence [3]. These approaches were not part of this
DCE, as such is it not possible to predict uptake for the full HIV
prevention arsenal. With the addition of pre-exposure prophylaxis
and treatment as prevention, one would expect uptake of all
options to be lower, while providing higher overall coverage.
However, the NPTs that are being developed, such as vaccines or
long acting injectable microbicides could completely alter the
landscape of HIV prevention.
It is well known that product attributes and individual
characteristics provide only partial insights into product accept-
ability. It is thus important to interpret the uptake predictions as
potential uptake, depending on levels of access, distribution
strategies employed and critical other household, partner,
contextual and organisation factors, as conceptualised by Mensch
et al. [50]. Factors relating to women’s preferences for distribution
outlets and product promotion have also been analysed within the
context of a sister study [52] and can provide some further insights
into access and uptake, but the full range of use factors needs to be
taken into account when considering potential introduction
strategies. Moreover, we have learned from recent HIV preven-
tion trials, such as MTN 003 [53], that willingness to try a new
product or be enrolled in a trial is very different from high
adherence/ consistent use at every sex-act, which is so critical to
product effectiveness and epidemiological impact.
This study has shown how much women value pregnancy
prevention, thus calling for continued investment in finding
products women can use to protect themselves both from HIV
and pregnancy, as noted by Holt [54]. Providing such multi-
indication prevention is likely to provide additional motivation for
high levels of adherence among women. We have shown how
Figure 4. Overview of coverage assumptions in modelling impact and cost-effectiveness oral prep, microbicides and vaccines
(2010–2013). The middle box represents the main estimate, with the vertical lines showing ranges included.
doi:10.1371/journal.pone.0083193.g004
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product effectiveness drives uptake and should therefore be
explicitly accounted for when modelling the impact of NPTs.
This study could provide provisional parameter values for women,
which could be improved with new DCE data providing estimates
of uptake for the full range of NPTs by their characteristics.
Conclusions
This study estimates the importance of product characteristics
on women’s likelihood of using a range of NPTs. It showed that
above all, women want highly effective products to protect
themselves from HIV. Women’s demand for such a product would
be greatly increased if NPTs could also prevent pregnancy.
Though most women expressed interest in these NPTs, it is
women who were not using condoms that were most keen to try
them. Although even a partially effective product is likely to
provide important protection for some women, it is critical to not
overestimate the uptake of a partially effective product. This
emphasises the importance of explicitly modelling the likely
interaction between product effectiveness and levels of predicted
uptake when modelling the epidemiological impact of introducing
any of the NPTs currently being considered for wide scale
introduction and using DCEs to collect preference data on the full
suite of NPTs now available.
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